Tests are also being carried out, or about to be launched, in China and the United States. A clinical trial to transfuse blood plasma from people recovered from Covid-19 to "patients with acute disease" will start on Tuesday in France.
"This clinical trial consists of the transfusion of plasma from cured patients of Covid-19, containing antibodies directed against the virus, and which could transfer this immunity to a patient suffering from Covid-19", details a joint press release from Assistance Public-Paris Hospitals (AP-HP), the French Blood Establishment (EFS) and the National Institute of Health and Medical Research (Inserm).
“The plasma of people who have recovered from Covid-19 contains these antibodies that their bodies have developed. These antibodies could help patients in the acute phase of the disease to fight the virus, ”they hope. This clinical trial, called Coviplasm, will be conducted by Professor Karine Lacombe and Professor Pierre Tiberghien.
200 patients sampled
Targeted samples will be taken from Tuesday in Ile-de-France, in the Grand-Est and in Bourgogne-Franche-Comté from around 200 patients who have been cured for at least 14 days. "Cured patients of Covid-19 will be personally invited to donate their plasma to the EFS," the statement said.
The clinical trial will count 60 patients in Parisian hospitals, of which "half will benefit from the plasma-convalescent supply". "An initial evaluation may be made two to three weeks after the start of the clinical trial", which may be extended depending on the results.
Podcast: diving under the microscope into the biology of coronaviruses
The EFS will also look for the presence of antibodies against the coronavirus "in a representative sample of blood donors coming to make a donation during a specific period", to "obtain an image of the spread of the virus in France".
Newsletter - The essentials of the news
Every morning, the news seen by Le ParisienI'm registering
Your email address is collected by Le Parisien to allow you to receive our news and commercial offers. Find out more
Convalescent plasma, the liquid part of the blood that concentrates antibodies after illness, has already proven to be effective in small-scale studies against other infectious diseases like Ebola or Sras.
